TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LEVOTHYROXINE SODIUM

LEVOTHYROXINE SODIUM
Oncology Approved 2002-06-05
22
Indications
--
Phase 3 Trials
23
Years on Market

LEVOTHYROXINE SODIUM Approval History

Loading approval history...

What LEVOTHYROXINE SODIUM Treats

2 indications

LEVOTHYROXINE SODIUM is approved for 2 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypothyroidism
  • Thyroid Cancer
Source: FDA Label

LEVOTHYROXINE SODIUM Boxed Warning

NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used ...

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVOTHYROXINE SODIUM FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Hypothyroidism Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: Levothyroxine sodium tablets are not ...

⚠️ BOXED WARNING

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements a...

LEVOTHYROXINE SODIUM Patents & Exclusivity

Latest Patent: Nov 2036

Patents (55 active)

US9782376 Expires Dec 1, 2036
US11135190 Expires Dec 1, 2036
US10398669 Expires Dec 1, 2036
US11154498 Expires Jul 20, 2036
US9006289 Expires Oct 3, 2032
US9168238 Expires Aug 29, 2032
US9168239 Expires Aug 29, 2032
+ 45 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.